Granules India Receives VAI Classification After US FDA Inspection

Granules India, a leading pharmaceutical manufacturer, disclosed that the US FDA inspection at its facility concluded without any major observations. The VAI classification indicates minor issues that do not warrant regulatory action, ensuring continued operations and exports to the US market.

Inspection Outcome
The inspection closure with VAI classification reflects Granules India’s adherence to international quality standards. The company emphasized that no Form 483 observations requiring corrective action were issued, highlighting its robust compliance framework.

Strategic Significance
This outcome is critical for Granules India, as the US remains one of its largest markets. The clearance ensures uninterrupted supply of key formulations and APIs, bolstering investor confidence and reinforcing the company’s reputation for regulatory compliance.

Key Highlights

• US FDA inspection at Granules India facility closed
• VAI classification received, no regulatory action recommended
• Ensures uninterrupted exports to US market
• Strengthens compliance and investor confidence
• Reinforces position in global pharmaceutical supply chain

Sources: Reuters, Business Standard, Economic Times, Mint